Navigation Links
URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
Date:11/8/2007

PLEASANTON, Calif., Nov. 8 /PRNewswire-FirstCall/ -- Thoratec Corporation initiated a worldwide recall on October 19, 2007 involving all Implantable Ventricular Assist Devices (IVAD) having Catalogue No. 10012-2555-001, serial numbers 488 or higher and manufactured and distributed since October 2004. The current Instructions for Use state that IVADs may be implanted in the pre-peritoneal (internal) position or placed in the paracorporeal (external) position. In the paracorporeal position, the pneumatic driveline is entirely external to the patient and may be damaged if the driveline is bent at a sharp angle relative to its junction with the pump housing which could cause a reduction or interruption of circulatory support, potentially resulting in serious injury or death.

The affected IVADs were distributed directly to 87 hospitals throughout the United States and other countries. They can be identified by the serial number located both on the label of the sterile package and on the Y-connector at the end of the IVAD percutaneous driveline.

The firm voluntarily issued an Urgent Medical Device Correction notice with new instructions regarding placement and care of the IVAD driveline after learning of pneumatic leaks associated with certain surgical orientations of the pump when used in the paracorporeal position. In one incident a death resulted when a damaged driveline severed at its connection to the pump. Drivelines may be damaged when the driveline connection to the pump impinges on the patient's leg when the patient is in the sitting position. This may cause excessive stress on the driveline, resulting in damage and pneumatic leaks. FDA has been apprised of this action. This action does not affect IVADs implanted in the pre-peritoneal or other internal positions.

Thoratec has received seven reports of damaged drivelines in paracorporeal IVADs, five of which resulted in patient injuries and one in a patient death. These seven reports come from approximately 45 IVADs placed in the paracorporeal position.

Until further notice, Thoratec is voluntarily advising that IVADs not be placed in the paracorporeal position, pending evaluation of any measures needed to prevent additional incidents of this type. Patients who are currently being supported by a Thoratec IVAD placed in the paracorporeal position (i.e. an external pump supporting blood circulation) should immediately contact their doctor. Your doctor will be able to determine if the driveline is properly positioned to minimize the amount of sharp bending. Hospitals were requested in the October 19, 2007 Recall Notification Letter to evaluate the driveline adjacent to the pump housing to ensure that it is not subject to extreme flexing or bending at acute angles on all patients currently on paracorporeal IVAD support. Hospitals having ongoing patients with IVADs in the paracorporeal position should contact Thoratec for further instructions if they did not receive the October 19, 2007 Recall Notification Letter. Copies of this press release may be found on Thoratec's website, http://www.thoratec.com, under Investor Relations/Press Releases.

Customers and patients with questions may contact the company at 1-800-528-2577.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

* Online: http://www.fda.gov/medwatch/report.htm

* Regular Mail: use postage-paid FDA form 3500 available at:

http://www.fda.gov/MedWatch/getforms.htm.

Mail to MedWatch 5600 Fishers Lane, Rockville, MD

20852-9787

* Fax: 1-800-FDA-0178


'/>"/>
SOURCE Thoratec Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Health IT Now! Coalition to Discuss the Urgent Need to Pass Health IT Legislation
2. Americans consider global warming an urgent threat, according to poll
3. Thoratec Schedules Third Quarter Conference Call, Webcast
4. Thoratecs ITC Division Receives FDA Warning Letter
5. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
6. Brooke Franchise Corporation Announces Selected July Results
7. MedThink Communications Retained by NanoBio Corporation
8. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
9. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
10. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
11. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: